Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Oesophageal Cancer
- Sponsor
- Royal Marsden NHS Foundation Trust
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.
- Last Updated
- 10 years ago
Overview
Brief Summary
Knowledge of the impact of gene expression profiling could allow optimisation of chemotherapy regimens for individual patients. It could ensure that patients do not receive a particular form of chemotherapy if it is unlikely to benefit them, and in these circumstances an alternative form of chemotherapy that may prove beneficial could be selected. This information will therefore allow chemotherapy to be tailored to the individual tumour. It may help identify those patients with a poorer prognosis who could be selected for further therapy post surgery or a different treatment strategy at the outset.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Any patient with histologically proven operable ,locally advanced and metastatic oesophageal or gastric carcinoma.
Exclusion Criteria
- •Second malignancy
Outcomes
Primary Outcomes
To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.
Secondary Outcomes
- Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.